CT/NG 測試市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、測試類型、技術、最終用戶、地區和競爭細分，2019-2029 年

2023 年，全球CT/NG 檢測市場價值為16.6 億美元，到2029 年，預測期內將以8.79% 的複合年成長率實現令人印象深刻的成長。性傳染病引起的感染的過程。這些感染在世界各地普遍存在，如果不及時治療，可能會導致嚴重的健康併發症。 CT/NG 檢測在識別感染、啟動適當治療和防止進一步傳播方面發揮著至關重要的作用。 CT/NG 檢測的主要目的是檢測從疑似患有性傳染感染 (STI) 的個體採集的生殖器、直腸或咽部標本中是否存在沙眼衣原體和淋病奈瑟菌。檢測的目的是識別活動性感染，即使是無症狀個體，以促進及時治療並防止疾病傳播。 CT/NG 檢測需要收集適當的臨床標本，包括尿液、生殖器拭子（尿道、陰道、子宮頸）、直腸拭子或咽拭子，取決於疑似感染部位和患者人口統計資料。應使用標準化程序收集樣本並運送至實驗室進行分析。有多種測試方法可用於 CT/NG 檢測，包括核酸擴增測試 (NAAT)、聚合酶鍊式反應 (PCR) 測定、轉錄介導的擴增 (TMA) 和基於培養的技術。 NAAT 和 PCR 檢測因其高靈敏度、特異性和快速週轉時間而成為最常用的方法。

市場概況
預測期	2025-2029
2023 年市場規模	16.6億美元
2029 年市場規模	27.6億美元
2024-2029 年複合年成長率	8.79%
成長最快的細分市場	檢測方法和試劑盒
最大的市場	北美洲

旨在提高人們對衣原體和淋病感染的認知和早期發現的公共衛生措施、教育活動和性傳染感染篩檢計畫推動了對 CT/NG 檢測的需求。認知的提高鼓勵個人尋求檢測服務並減少與性傳染感染相關的恥辱。核酸擴增檢測 (NAAT)、聚合酶鍊式反應 (PCR) 和即時護理 (POC) 檢測平台等診斷檢測方法的技術進步顯著提高了 CT/NG 的準確性、靈敏度和速度測試。這些進步使得能夠快速、可靠地檢測感染，推動市場成長。淋病奈瑟菌抗生素抗藥性菌株的出現對公共衛生構成了重大威脅，並強調了準確及時 CT/NG 檢測的重要性。對抗菌素抗藥性進行有效監測、診斷和管理的需求刺激了對 CT/NG 檢測解決方案的需求。

主要市場促進因素

診斷技術的進步

提高認知和篩檢計劃

抗生素抗藥性發生率增加

主要市場挑戰

與性傳染感染相關的恥辱

成本限制

主要市場趨勢

轉向分子診斷

細分市場洞察

產品洞察

技術洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球 CT/NG 檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（檢測及試劑盒、儀器/分析儀）
  • 依測試類型（實驗室測試、PoC 測試）
  • 依技術分類（免疫診斷、等溫核酸擴增技術、聚合酶鍊式反應）
  • 按最終使用者（臨床實驗室、醫院和診所、其他）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖

第 6 章：北美 CT/NG 檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲 CT/NG 檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太 CT/NG 檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲 CT/NG 檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲 CT/NG 檢測市場展望

• 市場規模及預測
• 市佔率及預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 13 章：全球 CT/NG 檢測市場：SWOT 分析

第14章：競爭格局

• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories Inc.
• QIAGEN NV
• PerkinElmer Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Danaher Corporation
• Becton, Dickinson, and Company

第 15 章：策略建議

第16章調查會社について,免責事項

Global CT/NG Testing Market was valued at USD 1.66 billion in 2023 and will see an impressive growth in the forecast period at a CAGR of 8.79% through 2029. CT/NG testing refers to the process of diagnosing infections caused by two common sexually transmitted bacteria: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). These infections are prevalent worldwide and can lead to serious health complications if left untreated. CT/NG testing plays a crucial role in identifying infections, initiating appropriate treatment, and preventing further transmission. The primary purpose of CT/NG testing is to detect the presence of Chlamydia trachomatis and Neisseria gonorrhoeae bacteria in genital, rectal, or pharyngeal specimens collected from individuals suspected of having a sexually transmitted infection (STI). Testing aims to identify active infections, even in asymptomatic individuals, to facilitate timely treatment and prevent the spread of disease. CT/NG testing requires the collection of appropriate clinical specimens, including urine, genital swabs (urethral, vaginal, cervical), rectal swabs, or pharyngeal swabs, depending on the suspected site of infection and patient demographics. Specimens should be collected using standardized procedures and transported to the laboratory for analysis. Several testing methods are available for CT/NG detection, including nucleic acid amplification tests (NAATs), polymerase chain reaction (PCR) assays, transcription-mediated amplification (TMA), and culture-based techniques. NAATs and PCR assays are the most used methods due to their high sensitivity, specificity, and rapid turnaround times.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 1.66 Billion
Market Size 2029	USD 2.76 Billion
CAGR 2024-2029	8.79%
Fastest Growing Segment	Assays and Kits
Largest Market	North America

Public health initiatives, educational campaigns, and STI screening programs aimed at promoting awareness and early detection of chlamydia and gonorrhea infections drive the demand for CT/NG testing. Increased awareness encourages individuals to seek testing services and reduces the stigma associated with STIs. Technological advancements in diagnostic testing methodologies, such as nucleic acid amplification tests (NAATs), polymerase chain reaction (PCR), and point-of-care (POC) testing platforms, have significantly improved the accuracy, sensitivity, and speed of CT/NG testing. These advancements enable rapid and reliable detection of infections, driving market growth. The emergence of antibiotic-resistant strains of Neisseria gonorrhoeae poses a significant public health threat and underscores the importance of accurate and timely CT/NG testing. The need for effective surveillance, diagnosis, and management of antimicrobial resistance fuels the demand for CT/NG testing solutions.

Key Market Drivers

Advancements in Diagnostic Technologies

Nucleic Acid Amplification Tests (NAATs) have become the gold standard for CT/NG testing due to their high sensitivity and specificity. These molecular diagnostic assays amplify and detect the genetic material of Chlamydia trachomatis and Neisseria gonorrhoeae, enabling accurate detection even at low pathogen concentrations. Polymerase Chain Reaction (PCR) Technology allows for the amplification and detection of specific DNA sequences associated with CT and NG infections. Real-time PCR assays offer rapid results and quantitative analysis, enhancing the efficiency and accuracy of CT/NG testing.

Transcription-Mediated Amplification (TMA) is another molecular amplification technique used for CT/NG testing. TMA assays amplify RNA targets, offering high sensitivity and specificity for the detection of chlamydia and gonorrhea infections. Multiplex PCR assays enable the simultaneous detection of multiple pathogens, including CT and NG, in a single reaction. These assays improve efficiency, reduce turnaround times, and enhance the cost-effectiveness of CT/NG testing. POC testing platforms allow for rapid, on-site detection of CT and NG infections, eliminating the need for sample transportation and centralized laboratory testing. POC tests offer convenience, portability, and immediate results, facilitating timely diagnosis and treatment in various healthcare settings.

Automated laboratory systems streamline CT/NG testing workflows, from sample processing to result interpretation. These systems offer high throughput, reduced hands-on time, and improved workflow integration, enhancing laboratory efficiency and productivity. Some CT/NG testing assays utilize room-temperature stable reagents and consumables, eliminating the need for cold storage and transportation. This feature improves assay stability, reduces logistical challenges, and enhances the accessibility of CT/NG testing in resource-limited settings. Next-Generation Sequencing (NGS) technologies offer advanced genomic analysis capabilities for CT/NG testing, allowing for comprehensive characterization of bacterial strains, antimicrobial resistance patterns, and genetic variations. NGS-based assays contribute to the surveillance of STI outbreaks and the development of targeted treatment strategies. This factor will help in the development of the Global CT/NG Testing Market.

Growing Awareness and Screening Programs

Public health campaigns, educational initiatives, and media awareness efforts increase knowledge about sexually transmitted infections (STIs) and the importance of regular screening for chlamydia and gonorrhea. These campaigns aim to reduce stigma, promote open communication about sexual health, and encourage individuals to seek testing services. Increased awareness about the risks associated with unprotected sexual activity and the prevalence of STIs motivates individuals to take proactive measures to prevent infection. Knowledge about the potential consequences of untreated chlamydia and gonorrhea, such as infertility, pelvic inflammatory disease, and increased HIV transmission risk, underscores the importance of early detection through screening.

Screening programs target high-risk populations, including sexually active individuals, adolescents, young adults, men who have sex with men (MSM), and individuals living with HIV/AIDS. Outreach efforts aim to reach underserved communities, marginalized populations, and individuals with limited access to healthcare services, ensuring equitable access to CT/NG testing and treatment. Screening for chlamydia and gonorrhea is increasingly integrated into routine healthcare services, including primary care, reproductive health clinics, family planning centers, and community health programs. Healthcare providers offer non-judgmental counseling, risk assessment, and confidential testing to individuals seeking sexual health services.

Efforts to improve the accessibility and affordability of CT/NG testing services contribute to increased uptake and demand. Public health initiatives, subsidized testing programs, and free or low-cost testing options reduce financial barriers and facilitate access to screening for individuals of all socioeconomic backgrounds. Clinical guidelines recommend routine screening for chlamydia and gonorrhea among sexually active individuals, adolescents, pregnant women, and other high-risk groups. Healthcare providers play a crucial role in promoting screening guidelines, offering evidence-based recommendations, and advocating for regular testing as part of preventive healthcare practices. Awareness of the importance of partner notification and contact tracing in STI prevention and control encourages individuals diagnosed with chlamydia or gonorrhea to inform their sexual partners and encourage them to seek testing and treatment. Partner notification services facilitate early diagnosis and treatment of infections, preventing further transmission within sexual networks. This factor will pace up the demand of the Global CT/NG Testing Market.

Increasing Incidence of Antibiotic Resistance

Both CT and NG have shown the ability to develop resistance to commonly used antibiotics, such as azithromycin and ceftriaxone, which are first-line treatments for these infections. The emergence of resistant strains compromises the effectiveness of standard antibiotic therapies, leading to treatment failures and persistent infections. Antibiotic-resistant CT and NG infections pose a significant public health threat, as they can result in severe complications, including pelvic inflammatory disease (PID), infertility, ectopic pregnancy, and increased risk of HIV transmission. Untreated or inadequately treated infections can also contribute to the spread of antibiotic resistance within communities and populations.

The rise of antibiotic resistance underscores the importance of targeted treatment strategies based on antimicrobial susceptibility testing. CT/NG testing allows healthcare providers to identify the presence of resistant strains, tailor treatment regimens accordingly, and optimize patient outcomes. CT/NG testing results inform treatment decisions by identifying the most effective antibiotics for individual patients. Antimicrobial susceptibility testing helps guide antibiotic selection, dosage adjustments, and treatment duration, minimizing the risk of treatment failure and the development of further resistance.

CT/NG testing contributes to the surveillance of antibiotic resistance patterns and trends at the local, national, and global levels. Surveillance data inform public health authorities, policymakers, and healthcare providers about the prevalence of resistant strains, emerging resistance mechanisms, and the effectiveness of current treatment guidelines. Early detection and appropriate management of antibiotic-resistant CT and NG infections are critical for preventing the spread of resistance within populations. CT/NG testing facilitates prompt diagnosis, contact tracing, partner notification, and targeted interventions to contain outbreaks and reduce transmission rates. CT/NG testing supports antimicrobial stewardship efforts by promoting judicious use of antibiotics and minimizing the overuse or misuse of antimicrobial agents. Testing enables healthcare providers to prescribe antibiotics selectively, avoid unnecessary treatment, and preserve the efficacy of available antibiotics for future use. This factor will accelerate the demand of the Global CT/NG Testing Market.

Key Market Challenges

Stigma Associated with STI

Stigma surrounding STIs, including chlamydia and gonorrhea, can act as a barrier to seeking testing and treatment. Individuals may feel ashamed, embarrassed, or fearful of judgment if they suspect they have an STI, leading them to avoid or delay testing and medical care. Concerns about privacy and confidentiality may deter individuals from disclosing their STI status or seeking testing services. Fear of social stigma, discrimination, and negative consequences, such as relationship issues or damage to reputation, can prevent individuals from accessing CT/NG testing and support services. The stigma associated with STIs can have negative effects on mental health and well-being. Individuals may experience feelings of shame, guilt, anxiety, depression, and self-blame, further exacerbating the reluctance to seek testing and treatment for chlamydia and gonorrhea infections. Stigmatization of STIs may contribute to disparities in healthcare access and utilization, particularly among marginalized populations, minority communities, and vulnerable groups. Structural barriers, including lack of insurance, transportation, and culturally competent healthcare services, further limit access to CT/NG testing and support resources.

Cost Constraints

The cost of CT/NG testing can be prohibitive for individuals, particularly those without health insurance or access to subsidized healthcare services. Out-of-pocket expenses for diagnostic tests, laboratory fees, healthcare consultations, and treatment regimens may pose financial barriers to accessing testing and care for chlamydia and gonorrhea infections. Individuals may face financial hardship or economic strain due to the cost of CT/NG testing, especially if they require repeat testing, follow-up appointments, or treatment for recurrent infections. High testing costs may deter individuals from seeking timely screening, resulting in delayed diagnosis and increased risk of complications. Health insurance coverage for CT/NG testing and related services varies widely depending on insurance plans, policies, and reimbursement schemes. Some insurance plans may cover CT/NG testing as part of preventive care or diagnostic services, while others may require co-payments, deductibles, or coverage limitations, creating disparities in access to testing based on insurance status. Individuals without health insurance or those covered by high-deductible health plans may face significant out-of-pocket expenses for CT/NG testing and treatment. The burden of paying for testing services upfront or covering deductible costs may deter individuals from seeking testing, resulting in missed opportunities for early detection and treatment of infections.

Key Market Trends

Shift towards Molecular Diagnostics

Molecular diagnostic techniques, such as NAATs and PCR assays, offer superior sensitivity and specificity compared to traditional methods like culture and antigen detection tests. They can detect even low levels of CT/NG genetic material, improving the accuracy of diagnosis. Molecular diagnostic tests for CT/NG typically provide faster results compared to traditional methods, which may require several days for culture-based techniques. NAATs and PCR assays can deliver results within a few hours, enabling timely initiation of treatment and contact tracing. Many molecular diagnostic platforms offer multiplexing capabilities, allowing simultaneous detection of multiple pathogens in a single test. This feature is particularly beneficial for CT/NG testing, as it allows for comprehensive screening for other STIs or co-infections. Molecular diagnostic platforms are often automated, streamlining laboratory workflows and reducing hands-on time. Automated systems improve efficiency, reduce the risk of human error, and increase testing throughput, making them suitable for high-volume testing environments.

Segmental Insights

Product Insights

The Assays and Kits segment is projected to experience rapid growth in the Global CT/NG Testing Market during the forecast period. The rising prevalence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections worldwide has fueled the demand for reliable and efficient diagnostic solutions. Assays and kits provide ready-to-use reagents and protocols for CT/NG testing, simplifying laboratory workflows and facilitating accurate and timely diagnosis of infections. Advances in molecular biology, genomics, and diagnostic technologies have led to the development of highly sensitive and specific assays and kits for CT/NG detection. These innovative solutions offer improved performance, reduced turnaround times, and enhanced ease of use compared to traditional testing methods, driving their adoption in clinical practice. Many assays and kits are designed to detect multiple pathogens, including CT and NG, in a single reaction. Multiplexing capabilities enable laboratories to simultaneously screen for multiple infections, increasing testing efficiency and throughput. This feature is particularly valuable in settings where resources and testing capacity are limited.

Technology Insights

The Polymerase Chain Reaction segment is projected to experience rapid growth in the Global CT/NG Testing Market during the forecast period. PCR-based assays offer high sensitivity and specificity in detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections, allowing for accurate diagnosis even at low pathogen concentrations. This reliability makes PCR a preferred method for CT/NG testing. PCR assays can simultaneously detect multiple pathogens, including CT and NG, in a single reaction, which enhances efficiency and reduces testing time. Multiplexing capabilities enable laboratories to streamline testing processes and improve throughput, making PCR an attractive option for high-volume testing. Advances in PCR technology have led to the development of automated PCR platforms that streamline sample processing, amplification, and result interpretation. These systems offer improved workflow integration, minimize hands-on time, and reduce the risk of cross-contamination, thereby enhancing laboratory efficiency and productivity.

Regional Insights

North America emerged as the dominant region in the Global CT/NG Testing Market in 2023. North America boasts a highly developed healthcare infrastructure with advanced diagnostic facilities, research institutions, and healthcare systems. This infrastructure enables widespread access to CT/NG testing services across the region, facilitating early detection and treatment of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections. North America experiences a relatively high prevalence of sexually transmitted infections (STIs), including chlamydia and gonorrhea. The region's large population, urbanization, and diverse demographics contribute to the spread of STIs, driving the demand for CT/NG testing among sexually active individuals, adolescents, and high-risk populations. North America adheres to stringent regulatory standards and quality assurance measures for diagnostic testing. Regulatory agencies such as the US Food and Drug Administration (FDA) and Health Canada ensure that CT/NG testing assays and devices meet rigorous criteria for safety, efficacy, and performance, instilling confidence among healthcare providers and patients.

Key Market Players

F. Hoffmann-La Roche Ltd.

Hologic, Inc.

Thermo Fisher Scientific Inc.

Abbott Laboratories Inc.

QIAGEN N.V.

PerkinElmer Inc.

Bio-Rad Laboratories, Inc.

Siemens Healthineers AG

Danaher Corporation

Becton, Dickinson, and Company

Report Scope:

In this report, the Global CT/NG Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CT/NG Testing Market, By Product:

Assays and Kits Instruments/Analyzers

CT/NG Testing Market, By Testing Type:

Lab Tests PoC Tests

CT/NG Testing Market, By Technology:

Immunodiagnostics Isothermal Nucleic Acid Amplification Technology Polymerase Chain Reaction

CT/NG Testing Market, By End User:

Clinical Laboratories Hospitals & Clinics Others

CT/NG Testing Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Asia-Pacific

China

Japan

India

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CT/NG Testing Market.

Available Customizations:

Global CT/NG Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CT/NG Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Assays and Kits, Instruments/Analyzers)
  • 5.2.2. By Testing Type (Lab Tests, PoC Tests)
  • 5.2.3. By Technology (Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction)
  • 5.2.4. By End User (Clinical Laboratories, Hospitals & Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2023)
• 5.3. Market Map

6. North America CT/NG Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Testing Type
  • 6.2.3. By Technology
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States CT/NG Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Testing Type
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada CT/NG Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Testing Type
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico CT/NG Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Testing Type
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By End User

7. Europe CT/NG Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Testing Type
  • 7.2.3. By Technology
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany CT/NG Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Testing Type
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom CT/NG Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Testing Type
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy CT/NG Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Testing Type
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By End User
  • 7.3.4. France CT/NG Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Testing Type
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain CT/NG Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Testing Type
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By End User

8. Asia-Pacific CT/NG Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Testing Type
  • 8.2.3. By Technology
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China CT/NG Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Testing Type
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By End User
  • 8.3.2. India CT/NG Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Testing Type
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan CT/NG Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Testing Type
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea CT/NG Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Testing Type
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia CT/NG Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Testing Type
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By End User

9. South America CT/NG Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Testing Type
  • 9.2.3. By Technology
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil CT/NG Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Testing Type
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina CT/NG Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Testing Type
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia CT/NG Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Testing Type
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By End User

10. Middle East and Africa CT/NG Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Testing Type
  • 10.2.3. By Technology
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa CT/NG Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Testing Type
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia CT/NG Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Testing Type
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE CT/NG Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Testing Type
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global CT/NG Testing Market: SWOT Analysis

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Product & Service Offerings
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel
  • 14.1.7. SWOT Analysis
• 14.2. Hologic, Inc.
• 14.3. Thermo Fisher Scientific Inc.
• 14.4. Abbott Laboratories Inc.
• 14.5. QIAGEN N.V.
• 14.6. PerkinElmer Inc.
• 14.7. Bio-Rad Laboratories, Inc.
• 14.8. Siemens Healthineers AG
• 14.9. Danaher Corporation
• 14.10.Becton, Dickinson, and Company

15. Strategic Recommendations

16. About Us & Disclaimer